GlassScriptPhysician profile
Thomas C Gavin
NPI 1932252756
$9,785.79
in general payments reported to CMS, 2019-2025
36 companies · $2,085 in 2025
The $2,085 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,808 · 2022: $1,857 · 2023: $1,895 · 2024: $2,141 · 2025: $2,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,120.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,131.37 | 2021-2025 | |
| Novo Nordisk INC | $1,364.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,321.41 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $878.39 | 2021-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $769.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $699.20 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $335.54 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $287.85 | 2022-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.05 | 2021-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $234.31 | 2021 | |
| Astellas Pharma US INC | $191.80 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $185.11 | 2021-2024 | Spravato, Invega Sustenna |
| Biohaven Pharmaceutical Holding Company LTD. | $155.94 | 2022 | |
| Lundbeck LLC | $135.52 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $95.94 | 2022-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.